Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

969 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer.
Manegold C, Drings P, von Pawel J, Ricci S, Dornoff W, van Walree N, ten Bokkel Huinink W, Chemaissani A, Stahel P, Bergman B, Wagenius G, Sederholm C, Mattson K, Liippo K, Kellokumpu-Lehtinen P. Manegold C, et al. Among authors: ricci s. Semin Oncol. 1997 Jun;24(3 Suppl 8):S8-13-S8-17. Semin Oncol. 1997. PMID: 9207310 Clinical Trial.
Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer.
Manegold C, Bergman B, Chemaissani A, Dornoff W, Drings P, Kellokumpu-Lehtinen P, Liippo K, Mattson K, van Pawel J, Ricci S, Sederholm C, Stahel RA, Wagenius G, van Walree N, ten Bokkel-Huinink W. Manegold C, et al. Among authors: ricci s. Ann Oncol. 1997 Jun;8(6):525-9. doi: 10.1023/a:1008207731111. Ann Oncol. 1997. PMID: 9261520 Free article. Clinical Trial.
Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer.
ten Bokkel Huinink WW, Bergman B, Chemaissani A, Dornoff W, Drings P, Kellokumpu-Lehtinen PL, Liippo K, Mattson K, von Pawel J, Ricci S, Sederholm C, Stahel RA, Wagenius G, Walree NV, Manegold C. ten Bokkel Huinink WW, et al. Among authors: ricci s. Lung Cancer. 1999 Nov;26(2):85-94. doi: 10.1016/s0169-5002(99)00067-7. Lung Cancer. 1999. PMID: 10568679 Clinical Trial.
Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project.
Crinò L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, Gridelli C, Ceribelli A, Bianco R, Marangolo M, Di Costanzo F, Sassi M, Barni S, Ravaioli A, Adamo V, Portalone L, Cruciani G, Masotti A, Ferrara G, Gozzelino F, Tonato M. Crinò L, et al. Among authors: ricci s. J Clin Oncol. 1999 Nov;17(11):3522-30. doi: 10.1200/JCO.1999.17.11.3522. J Clin Oncol. 1999. PMID: 10550150 Clinical Trial.
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.
Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, Matano E, Boni C, Marangolo M, Failla G, Altavilla G, Adamo V, Ceribelli A, Clerici M, Di Costanzo F, Frontini L, Tonato M; Italian Lung Cancer Project. Scagliotti GV, et al. Among authors: ricci s. J Clin Oncol. 2002 Nov 1;20(21):4285-91. doi: 10.1200/JCO.2002.02.068. J Clin Oncol. 2002. PMID: 12409326 Clinical Trial.
Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the "polmone toscano group" (POLTO).
Tibaldi C, Ricci S, Russo F, Bernardini I, Galli L, Chioni A, Orlandini C, Grosso AM, Pegna AL, Fabbri A, Innocenti F, Ferrari K, Tognarini L, Conte PF, Falcone A; POLTO group. Tibaldi C, et al. Among authors: ricci s. Lung Cancer. 2005 Apr;48(1):121-7. doi: 10.1016/j.lungcan.2004.10.008. Epub 2004 Dec 10. Lung Cancer. 2005. PMID: 15777979 Clinical Trial.
969 results